1. Home
  2. MGIC vs RVMDW Comparison

MGIC vs RVMDW Comparison

Compare MGIC & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGIC
  • RVMDW
  • Stock Information
  • Founded
  • MGIC 1983
  • RVMDW N/A
  • Country
  • MGIC Israel
  • RVMDW United States
  • Employees
  • MGIC N/A
  • RVMDW 443
  • Industry
  • MGIC Computer Software: Prepackaged Software
  • RVMDW
  • Sector
  • MGIC Technology
  • RVMDW
  • Exchange
  • MGIC Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • MGIC N/A
  • RVMDW N/A
  • IPO Year
  • MGIC 1991
  • RVMDW N/A
  • Fundamental
  • Price
  • MGIC $10.90
  • RVMDW $0.76
  • Analyst Decision
  • MGIC Buy
  • RVMDW
  • Analyst Count
  • MGIC 1
  • RVMDW 0
  • Target Price
  • MGIC $14.00
  • RVMDW N/A
  • AVG Volume (30 Days)
  • MGIC 32.5K
  • RVMDW N/A
  • Earning Date
  • MGIC 11-19-2024
  • RVMDW N/A
  • Dividend Yield
  • MGIC 1.87%
  • RVMDW N/A
  • EPS Growth
  • MGIC N/A
  • RVMDW N/A
  • EPS
  • MGIC 0.72
  • RVMDW N/A
  • Revenue
  • MGIC $523,332,000.00
  • RVMDW N/A
  • Revenue This Year
  • MGIC $3.87
  • RVMDW N/A
  • Revenue Next Year
  • MGIC $3.39
  • RVMDW N/A
  • P/E Ratio
  • MGIC $15.14
  • RVMDW N/A
  • Revenue Growth
  • MGIC N/A
  • RVMDW N/A
  • 52 Week Low
  • MGIC $8.27
  • RVMDW N/A
  • 52 Week High
  • MGIC $12.99
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • MGIC 43.68
  • RVMDW N/A
  • Support Level
  • MGIC $10.42
  • RVMDW N/A
  • Resistance Level
  • MGIC $11.14
  • RVMDW N/A
  • Average True Range (ATR)
  • MGIC 0.28
  • RVMDW 0.00
  • MACD
  • MGIC -0.05
  • RVMDW 0.00
  • Stochastic Oscillator
  • MGIC 36.64
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: